BIOMAT Database Logo BIOMAT Database Logo

[Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors]. 1993

K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Abteilung für Klinische Nuklearmedizin, Philipps-Universität Marburg, FRG.

Receptor scintigraphy with 111In-pentetreotide is a complementary imaging technique with a sensitivity of 88% for the localization of the primary tumor and its metastases in patients presenting with the clinical and biochemical symptoms of an endocrine tumor of the gastrointestinal tract or the pancreas. As a whole-body scintigraphic technique it covers all body regions and is also able to reveal small tumors which can only be detected with difficulty or not at all by the usual imaging methods. In 104 patients with GEP tumors or after operative removal of such tumors, receptor scintigraphy proved to be superior to ultrasound and computed tomography in 34%, equal in 52% and inferior in 14% of the cases.

UI MeSH Term Description Entries
D007205 Indium Radioisotopes Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes. Radioisotopes, Indium
D008297 Male Males
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D005260 Female Females
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D017481 Receptors, Somatostatin Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter. Receptors, Somatotropin Release Inhibiting Hormone,Somatostatin Receptors,Receptors, SRIH,SRIH Receptors,Somatostatin Receptor,Receptor, Somatostatin

Related Publications

K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.
December 2003, International journal of oncology,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
October 1994, Seminars in oncology,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors.
June 1994, Zeitschrift fur Gastroenterologie,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
July 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.
January 2017, American journal of nuclear medicine and molecular imaging,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
January 1997, Anticancer research,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
111In-pentetreotide scintigraphy in thyroid-associated orbitopathy.
January 1999, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
[Imaging of somatostatin receptor using 111In-pentetreotide].
April 1996, Kaku igaku. The Japanese journal of nuclear medicine,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
[Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
August 1995, Nuklearmedizin. Nuclear medicine,
K Joseph, and J Stapp, and J Reinecke, and H J Skamel, and H Höffken, and R Benning, and C Neuhaus, and H Lenze, and M E Trautmann, and R Arnold
Increased mammary uptake on 111In pentetreotide scintigraphy.
August 2012, Clinical nuclear medicine,
Copied contents to your clipboard!